ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025

Rhea-AI Summary

ADMA Biologics (Nasdaq: ADMA) will report third quarter 2025 financial results on November 5, 2025 after U.S. market close.

Management will host a live conference call and audio webcast on November 5, 2025 at 4:30 p.m. ET to discuss financial results and company updates. Participants must register to receive dial-in numbers and a unique PIN; joining ~10 minutes early is recommended. A live webcast will be available for listeners, and an archived replay will be posted under Events & Webcasts on the company investor site: https://ir.admabiologics.com/events-webcasts.

News Market Reaction

-0.26%

1 alert

-0.26% News Effect

On the day this news was published, ADMA declined 0.26%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Conference Call Scheduled for November 5, 2025, at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report third quarter 2025 financial results on November 5, 2025, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.

To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com

FAQ

When will ADMA (ADMA) report Q3 2025 results?

ADMA will report third quarter 2025 results on November 5, 2025, after U.S. markets close.

What time is the ADMA Q3 2025 conference call and webcast?

The live conference call and audio webcast is scheduled for November 5, 2025 at 4:30 p.m. ET.

How do I join the ADMA November 5, 2025 earnings call?

You must register in advance to receive dial-in numbers and a unique PIN; a live webcast link is also provided for listeners.

Will ADMA provide a replay of the November 5, 2025 call?

Yes. An archived replay will be posted under Events & Webcasts on ADMA's investor site at https://ir.admabiologics.com/events-webcasts.

Can I ask questions during ADMA's Q3 2025 call?

Yes. Participants who register and dial in can ask questions; those not asking are encouraged to listen via the live webcast.

Is the ADMA Q3 2025 release scheduled before or after market hours?

The results will be released after U.S. market close on November 5, 2025, with the call at 4:30 p.m. ET.